Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – June 2026 on 22 July, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Adam Cutler, CFO, […]
New record for sales growth and number of patients supported Product portfolio enhanced through acquisition of NanoBone® and expansion of STIMULAN® approval as an antibiotic carrier to treat bacterial infection Research and Development boosts with STIMULAN VG moving to phase II clinical trial and investment in Renovite Keele, UK, 13 December 2023 – Biocomposites, an international […]
Continued progress on XF-73 partnering discussions Susan Koppy appointed to drive business development activities $2bn XF-73 Nasal market opportunity Brighton, United Kingdom – 29th June 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections, today provides an update on the […]
Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets Prof. Julian Downward (Francis Crick Institute) and Prof. Steven Benkovic (Penn State University) join the Scientific Advisory Board Relocation to bespoke laboratories and offices at Southampton Science Park Read more…
Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]
